• LAST PRICE
    3.7800
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    3.5000/ 2
  • Ask / Lots
    3.8300/ 8
  • Open / Previous Close
    3.7000 / 3.7800
  • Day Range
    Low 3.5200
    High 3.8500
  • 52 Week Range
    Low 0.4600
    High 4.6834
  • Volume
    303,075
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 3.7
TimeVolumeTRVI
09:32 ET29253.7
09:39 ET10303.7
09:41 ET7073.655
09:48 ET34003.69
09:50 ET28583.77
09:52 ET6003.775
09:54 ET5203.78
09:56 ET5923.8
09:59 ET1003.8
10:01 ET1003.825
10:03 ET3003.85
10:06 ET4003.805
10:10 ET5003.81
10:12 ET4003.775
10:14 ET40883.68
10:15 ET20003.72
10:17 ET2003.74
10:19 ET6033.745
10:24 ET11503.8
10:37 ET34393.735
10:39 ET1003.72
10:44 ET23003.72
10:46 ET5113.75
10:48 ET4343.78
10:50 ET6333.79
10:51 ET12383.755
10:55 ET4153.755
11:00 ET6503.75
11:04 ET9103.77
11:06 ET2173.81
11:08 ET3003.81
11:18 ET98053.7464
11:20 ET4863.74
11:22 ET3123.77
11:24 ET13453.755
11:26 ET4003.76
11:27 ET1003.76
11:29 ET10413.75
11:31 ET13443.75
11:33 ET4003.76
11:38 ET4053.76
11:40 ET3003.78
11:42 ET4273.76
11:44 ET17763.755
11:47 ET3003.77
11:49 ET9163.755
11:51 ET14293.75
11:54 ET63283.72
11:56 ET31503.74
11:58 ET11003.74
12:02 ET6233.74
12:05 ET3173.75
12:07 ET6173.75
12:09 ET12003.755
12:12 ET1003.75
12:14 ET6313.76
12:16 ET13313.76
12:20 ET5003.75
12:21 ET5003.75
12:25 ET10713.75
12:27 ET5003.75
12:30 ET5223.765
12:32 ET4003.75
12:34 ET3003.75
12:36 ET6003.75
12:38 ET6213.7569
12:41 ET9003.75
12:43 ET2003.74
12:45 ET14123.75
12:48 ET20003.75
12:50 ET11003.75
12:52 ET17913.75
12:54 ET8003.76
12:56 ET24003.75
12:57 ET4003.75
12:59 ET4003.75
01:01 ET10003.75
01:03 ET19463.74
01:06 ET4003.735
01:10 ET18473.745
01:14 ET4243.745
01:15 ET4053.745
01:19 ET4083.745
01:24 ET4003.745
01:26 ET3223.75
01:30 ET10313.75
01:32 ET1003.75
01:33 ET5243.75
01:37 ET7203.75
01:39 ET10253.78
01:42 ET104983.71
01:46 ET2003.735
01:48 ET3193.735
01:50 ET1003.735
01:51 ET2003.735
01:53 ET9403.72
01:55 ET3003.72
01:57 ET22523.78
02:00 ET10643.775
02:02 ET17253.755
02:04 ET1003.755
02:06 ET4003.775
02:11 ET4073.795
02:13 ET13493.8015
02:18 ET2003.81
02:20 ET4423.8
02:22 ET2003.8
02:27 ET8053.8
02:29 ET2503.7999
02:33 ET2003.795
02:36 ET4173.805
02:45 ET2003.81
02:47 ET2003.81
02:51 ET1003.808
02:56 ET7003.82
03:00 ET1003.82
03:05 ET1003.82
03:12 ET25793.795
03:14 ET512353.52
03:16 ET134303.62
03:18 ET3003.63
03:20 ET19003.64
03:21 ET1003.64
03:23 ET6183.67
03:25 ET6213.7
03:27 ET9193.7
03:30 ET2003.685
03:32 ET12453.71
03:34 ET7213.725
03:36 ET11043.765
03:38 ET12203.755
03:39 ET24013.765
03:41 ET23283.79
03:43 ET15003.81
03:45 ET21503.795
03:48 ET12473.8
03:50 ET108053.72
03:52 ET29373.755
03:54 ET44213.81
03:56 ET16523.81
03:57 ET365733.72
03:59 ET149623.78
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesTRVI
Trevi Therapeutics Inc
164.8M
-2.8x
---
United StatesENZC
Enzolytics Inc
160.6M
-0.5x
---
United StatesTFFP
TFF Pharmaceuticals Inc
160.4M
-4.4x
---
United StatesETNB
89Bio Inc
163.9M
-0.9x
---
United StatesIMUX
Immunic Inc
157.1M
-1.7x
---
United StatesCELC
Celcuity Inc
156.9M
-4.0x
---
As of 2022-08-18

Company Information

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio (nalbuphine ER) to treat neurologically mediated conditions. It is engaged in developing Haduvio for the treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Haduvio is an oral extended-release (ER) formulation of nalbuphine. It is conducting Phase IIb/3 clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It is also conducting Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as Phase II CANAL trial. It has also commenced Phase Ib trial in patients with chronic liver disease to evaluate the safety, pharmacokinetics of Haduvio. Its Haduvio development programs include Active Chronic Pruritus Programs, Prurigo Nodularis Program, and Chronic Cough in Idiopathic Pulmonary Fibrosis Program.

Contact Information

Headquarters
195 Church St Fl 14NEW HAVEN, CT, United States 06510-2009
Phone
203-304-2499
Fax
203-304-2434

Executives

Chairman of the Board
David Meeker
President, Chief Executive Officer, Director
Jennifer Good
Co-Founder, Chief Medical Officer
Thomas Sciascia
Chief Financial Officer
Lisa Delfini
Chief Development Officer
William Forbes

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$164.8M
Revenue (TTM)
$0.00
Shares Outstanding
38.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.34
Book Value
$0.60
P/E Ratio
-2.8x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.